Inherent increase of apoptosis in liver tumors: Implications for carcinogenesis and tumor regression
B Grasl-Kraupp
Institut fur Tumurbiologie-Krebsforschunng der Universitat Wien, Austria
Search for more papers by this authorB Ruttkay-Nedecky
Institut fur Tumurbiologie-Krebsforschunng der Universitat Wien, Austria
Search for more papers by this authorL Mullauer
Institut fur Tumurbiologie-Krebsforschunng der Universitat Wien, Austria
Search for more papers by this authorH Taper
Institut fur Tumurbiologie-Krebsforschunng der Universitat Wien, Austria
Search for more papers by this authorW Huber
Institut fur Tumurbiologie-Krebsforschunng der Universitat Wien, Austria
Search for more papers by this authorW Bursch
Institut fur Tumurbiologie-Krebsforschunng der Universitat Wien, Austria
Search for more papers by this authorR Schulte-Hermann
Institut fur Tumurbiologie-Krebsforschunng der Universitat Wien, Austria
Search for more papers by this authorB Grasl-Kraupp
Institut fur Tumurbiologie-Krebsforschunng der Universitat Wien, Austria
Search for more papers by this authorB Ruttkay-Nedecky
Institut fur Tumurbiologie-Krebsforschunng der Universitat Wien, Austria
Search for more papers by this authorL Mullauer
Institut fur Tumurbiologie-Krebsforschunng der Universitat Wien, Austria
Search for more papers by this authorH Taper
Institut fur Tumurbiologie-Krebsforschunng der Universitat Wien, Austria
Search for more papers by this authorW Huber
Institut fur Tumurbiologie-Krebsforschunng der Universitat Wien, Austria
Search for more papers by this authorW Bursch
Institut fur Tumurbiologie-Krebsforschunng der Universitat Wien, Austria
Search for more papers by this authorR Schulte-Hermann
Institut fur Tumurbiologie-Krebsforschunng der Universitat Wien, Austria
Search for more papers by this authorAbstract
We quantitatively assessed rates of cell replication and of apoptosis during the development and regression of liver cancer. In rats, apoptotic activity gradually increased from normal liver to putative preneoplastic foci (PPF), to hepatocellular adenoma (HCA), and to hepatocellular carcinoma (HCC). At all stages, rates of cell replication were higher than of apoptosis, allowing a preferential net gain of (pre)neoplastic cells. As in rats, in human HCC, birth and death rates were increased manifold, indicating a species-independent phenomenon. Implications of the increasing cell turnover were studied in rats using the administration and withdrawal of nafenopin (NAF), a liver mitogen and nongenotoxic carcinogen. Prolonged NAF treatment enhanced cell number in normal liver by 25%, while PPF and liver tumors were amplified at least 100-fold. After stopping NAF treatment, cell replication ceased, while cell elimination by apoptosis was increased in normal and (pre)neoplastic liver. HCA and HCC showed the most pronounced shifts from replication toward apoptosis. As a result, 5 weeks after halting NAF, 20% of cells in normal liver, but about 85% of (pre)neoplastic lesions including HCC, were eliminated. The implications of these findings include that nongenotoxic carcinogens can act as survival factors even for malignant cells. Furthermore, tumor cells not only exhibit excessive proliferation, but also undergo apoptosis at rates that far exceed those in normal tissue. Therefore, inhibition of cell death by the survival activity of nongenotoxic carcinogens results in selective growth of (pre)neoplastic lesions. On the other hand, blockade of survival effects leads to excessive apoptosis in (pre)neoplasia and seems promising as a therapeutic concept for the selective elimination of (liver) cancer.
References
- 1 Cooper EH, Bedford AJ, Kenny TE. Cell death in normal and malignant tissues. Adv Cancer Res 1975; 21: 59–120.
- 2
Wright NA.
The tissue kinetics of cell loss.
In:
ID Bowen,
RA Lockshin, eds.
Cell Death in Biology and Pathology.
London, New York:
Chapman and Hall,
1981:
171–207.
10.1007/978-94-011-6921-9_7 Google Scholar
- 3 Wyllie AH. The biology of cell death in tumors. Anticancer Res 1985; 5: 131–136.
- 4 Sarraf CE, Bowen ID. Kinetic studies on a murine sarcoma and an analysis of apoptosis. Br J Cancer 1986; 54: 989–998.
- 5 Moore JV. Death of cells and necrosis of tumours. In: CS Potten, ed. Perspectives on Mammalian Cell Death. New York: Oxford University Press, 1987: 295–325.
- 6 Michalopoulos GK. Liver regeneration and growth factors: old puzzles and new perspectives. Lab Invest 1992; 67: 413–415.
- 7 Oberhammer FA, Pavelka M, Sharma S, Tiefenbacher R, Purchio AF, Bursch W, Schulte-Hermann R. Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor β. Proc Natl Acad Sci U S A 1992; 89: 5408–5412.
- 8 Fausto N, Webber EM. Mechanisms of growth regulation in liver regeneration and hepatic carcinogenesis. In: JL Boyer, RK Ockner, eds. Progress in Liver Diseases. Philadelphia, Saunders, 1993: 115–137.
- 9 Nagy P, Bisgaard HC, Thorgeirsson SS. Expression of hepatic transcriptional factors during liver development and oval cell differentiation. J Cell Biol 1994; 126: 223–233.
- 10 Grasl-Kraupp B, Bursch W, Ruttkay-Nedecky B, Wagner A, Lauer B, Schulte-Hermann R. Food restriction eliminates preneoplastic cells through apoptosis and antagonizes carcinogenesis in rat liver. Proc Natl Acad Sci U S A 1994; 91: 9996–9999.
- 11 Schulte-Hermann R, Bursch W, Grasl-Kraupp B. Active cell death (apoptosis) in liver biology and disease. In: JL Boyer, RK Ockner, eds. Progress in Liver Diseases. Philadelphia, Saunders, 1995: 1–35.
- 12 Okuda K, Kojiro M, Okuda H. Neoplasms of the liver. In: L Schiff, ER Schiff, eds. Diseases of the Liver. Philadelphia, Lippincott, 1993: 1236–1296.
- 13 Pitot HC, Dragan YP. Facts and theories concerning the mechanisms of carcinogenesis. FASEB J 1991; 5: 2280–2286.
- 14 Bursch W, Lauer B, Timmermann-Trosiener I, Barthel G, Schuppler J, Schulte-Hermann R. Controlled cell death (apoptosis) of normal and putative preneoplastic cells in rat liver following withdrawal of tumor promoters. Carcinogenesis 1984; 5: 453–458.
- 15 Schulte-Hermann R, Timmermann-Trosiener I, Barthel G, Bursch W. DNA synthesis, apoptosis, and phenotype expression as determinants of growth of altered foci in rat liver during phenobarbital promotion. Cancer Res 1990; 50: 5127–5135.
- 16 Lake BG. Mechanisms of hepatocarcinogenicity of peroxisome-proliferat-ing drugs and chemicals. Annu Rev Pharmacol Toxicol 1995; 35: 483–507.
- 17 Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347: 645–650.
- 18 Moody DE, Reddy JK. Morphometric analysis of the ultrastructural changes in rat liver induced by the peroxisome proliferator SaH 42–348. J Cell Biol 1976; 71: 768–780.
- 19 Greaves P, Irisarri E, Monro AM. Hepatic foci of cellular and enzymatic alteration and nodules in rats treated with clofibrate or diethylnitrosamine followed by phenobarbital: their rate of onset and their reversibility. J Natl Cancer Inst 1986; 76: 475–484.
- 20 Marsnian DS, Popp JA. Biological potential of basophilic hepatocellular foci and hepatic adenoma induced by the peroxisonie proliferator, Wy-14,643. Carcinogenesis 1994; 15: 111–117.
- 21 Kraupp-Grasl B, Huber W, Taper H, Schulte-Hermann R. Increased susceptibility of aged rats to hepatocarcinogenesis by the peroxisonie proliferator nafenopin and the possible involvement of altered liver foci occurring spontaneously. Cancer Res 1991; 51: 666–671.
- 22 Schulte-Hermann R. Two-stage control of cell proliferation induced in rat liver by alpha-hexachlorocyclohexane. Cancer Res 1977; 37: 166–171.
- 23 Saltykow SA. The determination of the size distribution of particles in opaque material from a measurement of the size distributions of their sections. In: H Elias, ed. Proceedings of the Second International Congress for Stereology. Berlin: Springer, 1967: 163–173.
- 24 Bursch W, Taper HS, Lauer B, Schulte-Hermann R. Quantitative histological and histochemical studies on the occurrence and stages of controlled cell death (apoptosis) during regression of rat liver hyperplasia. Virchows ArchB 1985; 50: 153–166.
- 25 Luebeck EG, Grasl-Kraupp B, Timmermann-Trosiener I, Bursch W, Schulte-Hermann R, Moolgavkar SH. Growth kinetics of enzyme-altered liver foci in rats treated with phenobarbital or alpha-hexachlorocyclohexane. Toxicol Appl Pharm 1995; 130: 304–315.
- 26
Edmondson HA,
Steiner PE.
Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.
Cancer
1954;
7:
462–503.
10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E CAS PubMed Web of Science® Google Scholar
- 27 Weidner N, Moore DH II, Vartanian R. Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel “paraffin”-reactive MIB1 antibody. Hum Pathol 1994; 25: 337–342.
- 28 Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugal T, Kitamura Y, Itoh N, et al. Lethal effect of the anti-fas antibody in mice. Nature 1993; 364: 806–809.
- 29 Szende B, Zalatnai A, Schally AV. Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatin. Proc Natl Acad Sci U S A 1989; 86: 1643–1647.
- 30 Bursch W, Liehr JG, Sirbasku D, Putz B, Taper H, Schulte-Hermann R. Control of cell death (apoptosis) by diethylstilbestrol in an estrogen-dependent kidney tumor. Carcinogenesis 1991; 12: 855–860.
- 31 Tenniswood MP, Guenette RS, Lakins J, Mooibroek M, Wong P, Welsh JE. Active cell death in hormone-dependent tissue. Cancer Metast Rev 1992; 77: 197–220.
- 32 Prehn RT. The inhibition of tumor growth by tumor mass. Cancer Res 1991; 51: 2–4.
- 33 Moolgavkar SH, Luebeck EG, de Gunst M, Port RE, Schwarz M. Quantitative analysis of enzyme-altered foci in rat hepatocarcinogenesis experiments I: single agent regimen. Carcinogenesis 1990; 11: 1271–1278.
- 34 Schulte-Hermann R, Ohde G, Schuppler J, Timmermann-Trosiener I. Enhanced proliferation of putative preneoplastic cells in rat liver following treatment with the tumor promoters phenobarbital, hexachlorocyclohexane, steroid compounds, and nafenopin. Cancer Res 1981; 41: 2556–2562.
- 35 Müllauer L, Grasl-Kraupp B, Bursch W, Schulte-Hermann R. Transforming growth factor β–induced cell death in preneoplastic foci of rat liver and sensitization by the antiestrogen tamoxifen. Hepatology 1996; 23: 840–847.
- 36
Sato Y,
Fujiwara K,
Nakagawa S,
Kanishima S,
Ohta Y,
Oka Y,
Hayashi S, et al.
A case of spontaneous regression of hepatocellular carcinoma with bone metastasis.
Cancer
1985;
56:
667–671.
10.1002/1097-0142(19850801)56:3<667::AID-CNCR2820560339>3.0.CO;2-S CAS PubMed Web of Science® Google Scholar
- 37
Gaffey MJ,
Joyce JP,
Carlson GS,
Esteban JM.
Spontaneous regression of hepatocellular carcinoma.
Cancer
1989;
65:
2779–2783.
10.1002/1097-0142(19900615)65:12<2779::AID-CNCR2820651228>3.0.CO;2-T PubMed Web of Science® Google Scholar
- 38 Suzuki M, Okazaki N, Yoshino M, Yoshida T. Spontaneous regression of a hepatocellular carcinoma–a case report. Hepatogastroenterology 1989; 36: 160–163.
- 39 Farrell GC, Joshua DE, Uren RF, Baird PJ, Perkins KW, Kronenberg H. Androgen-induced hepatoma. Lancet 1975; i: 430–432.
- 40 Edmondson HA, Reynolds TB, Henderson B, Benton B. Regression of liver cell adenoma associated with oral contraceptives. Ann Intern Med 1977; 86: 180–182.
- 41 Buhler H, Pirovino M, Akovbiantz A, Altorfer J, Weitzel M, Maranta E, Schmid M. Regression of liver cell adenoma. A follow up study of three consecutive patients after discontinuation of oral contraceptive use. Gastroenterology 1982; 82: 775–782.
- 42 Huggins C. Endocrine-induced regression of cancers. Cancer Res 1967; 27: 1925–1930.